Vopratelimab
- Generic Name
- Vopratelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2039148-04-2
- Unique Ingredient Identifier
- QXN20J93AH
- Background
Vopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT04549025
- Locations
- 🇺🇦
Kyiv Railway Clinical Hospital #3 of Branch Health Center of the PJSC Ukrainian Railway, Kyiv, Ukraine
🇬🇪Arensia Tbilisi - PPDS, Tbilisi, Georgia
ðŸ‡ðŸ‡ºVeszprem Megyei Tudogyogyintezet, Farkasgyepű, Hungary
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04319224
- Locations
- 🇺🇸
The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Virginia Health Systems, Charlottesville, Virginia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT03989362
- Locations
- 🇺🇸
University of Southern California Medical Center, Los Angeles, California, United States
🇺🇸University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.